Plasma prolidase levels as a biomarker for polycystic ovary syndrome. (6th June 2018)

• Record Type: Journal Article
• Authors: Bhatnager, Richa; Nanda, Smiti; Dang, Amita S
• Is Part Of: Biomarkers in medicine. Volume 12:Number 6(2018)
• Page Start: 597
• Page End: 606
• Publication Date: 2018-06-06
• Subjects: collagen -- diagnostic marker -- extracellular matrix -- PCOS -- polycystic ovaries -- prognostic marker -- prolidase -- ROC curve -- transvaginal ultrasonography; Biochemical markers -- Periodicals; 610.28
• DOI: 10.2217/bmm-2017-0306
• Languages: English
• ISSNs: 1752-0363

Abstract

Aim: Assessment of plasma prolidase levels in polycystic ovary syndrome (PCOS).Patients & methods: PCOS patients were screened according to Rotterdam Criterion and prolidase levels were measured.Results: A total of 170 patients and 160 controls were recruited for the study and it was found that prolidase levels were significantly higher in PCOS group (991.10 ± 39.52) than control (621.89 ± 23.94). Furthermore it has been found that prolidase levels increase with the number of cysts in ovaries.Conclusion: Significant difference between prolidase levels in PCOS and control shows that it may be used as a diagnostic marker for disease. In addition to this, there is a positive correlation found between prolidase levels and number of cysts, hence may be used as a prognostic marker to monitor disease status.